KURA — Kura Oncology, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1422143 ·
Last close
$7.49
Market Cap
$688.17M
52W High
$13.90
52W Low
$6.75
ADV30
2,217,159
Next earnings
—
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 22,839,000 22,468,000 -74,658,000 -70,215,000 566,497,000 57,937,000 548,537,000
Jun 2026 20,874,000 20,631,000 -73,010,000 -68,327,000 587,791,000 70,242,000 539,360,000
Mar 2026 18,265,000 18,003,000 -78,815,000 -73,333,000 652,551,000 39,083,000 544,668,000
Dec 2025 17,336,000 — -86,268,000 -80,999,000 738,363,000 149,099,000 564,228,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-85,574,000
Investing CF
$12,977,000
Financing CF
$35,247,000
CapEx
$-3,550,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.30
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,385,963,000
Inventory
$4,982,000
Receivables
$14,485,000
ST Investments
$434,159,000
EBIT TTM
$-291,413,000
Pretax Income TTM
$-292,790,000
Interest Exp TTM
$1,377,000
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$79,314,000
EBITDA
$-311,295,008
Free Cash Flow
$-111,096,000
Enterprise Value
$247,631,456
Total Cash
$492,096,000
Total Debt
$25,830,000
Shares Out
91,878,694
Trailing EPS
$-3.45
Book Value
$0.20
ROE
-224.9%
ROA
-32.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 67,482,000 -303,631,000 -278,666,000 738,363,000 564,228,000 174,135,000 -64,058,000
Dec 2024 53,883,000 -193,195,000 -173,983,000 760,159,000 346,519,000 413,640,000 134,317,000
Dec 2023 0 -165,804,000 -152,631,000 448,935,000 51,662,000 397,273,000 -124,824,000
Dec 2022 0 -139,865,000 -135,840,000 456,306,000 36,028,000 420,278,000 -110,062,000

TTM Snapshot

Revenues TTM
$77,225,000
NetIncome TTM
$-296,775,000
OpCashFlow TTM
—
Assets (Latest)
$587,791,000
Forward EPS
$-2.43

Max Pain — expiry 2027-01-15

max pain strike: $11.00 · spot: $7.34 · call oi: 3,470 · put oi: 2,687
Expected Move to 2027-01-15: ±$2.05 (27.93%) — implied range $5.29 – $9.39 · ATM straddle on $7.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SGMT Sagimet Biosciences Inc. $702.97M $9.85 —
ANNX Annexon, Inc. $661.95M $3.47 —
NVCT Nuvectis Pharma, Inc. $660.27M $19.20 —
JANX Janux Therapeutics, Inc. $655.27M $10.71 —
GERN GERON CORP $644.24M $1.00 —

News headlines (Yahoo Finance, 1h cache)

Kura Oncology to Participate in Two Investor Conferences in November
2026-11-13 17:33 · Yahoo
Kura Oncology, Inc. Q3 2026 Earnings Call Summary
2026-11-11 13:30 · Yahoo
Kura Oncology Inc (KURA) (Q3 2026) Earnings Call Highlights: KOMZIFTI Revenue Surges 53% as ...
2026-11-11 07:08 · Yahoo
Kura Oncology (KURA) Q3 2026 Earnings Call Transcript
2026-11-11 05:31 · Yahoo
Kura Oncology Q3 Earnings Call Highlights
2026-11-11 01:14 · Yahoo
Kura Oncology: Q3 Earnings Snapshot
2026-11-10 21:25 · Yahoo
Kura Oncology (KURA) Reports Q3 Loss, Beats Revenue Estimates
2026-11-10 21:20 · Yahoo
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
2026-11-10 21:02 · Yahoo
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 12:30 · Yahoo
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
2026-11-04 14:02 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-16 19:45:03 2026-11-13 Wilson Troy Edward Pres, CEO P - Purchase 7.52 200000 1504765